2-Hydroxy-11-(2-methylallyl)oxynoraporphine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2-Hydroxy-11-(2-methylallyl)oxynoraporphine is a serotonin 5-HT2A and 5-HT2C receptor agonist of the noraporphine family.[1][2] It is a synthetic compound and is an analogue of aporphine alkaloids like nuciferine, but shows agonism rather than antagonism of serotonin 5-HT2 receptors.[1][2]
oxynoraporphine.svg)
- None
| |
| Clinical data | |
|---|---|
| Other names | "Compound 20s";[1] "Compound S30"[2] |
| Drug class | Serotonin 5-HT2A receptor agonist; Serotonin 5-HT2C receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C20H21NO2 |
| Molar mass | 307.393 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It is a potent full agonist or high-efficacy partial agonist of the serotonin 5-HT2A and 5-HT2C receptors.[1][2] The drug's EC50 (Emax) values were 6.3 to 9.4 nM (83–84%) at the serotonin 5-HT2A receptor and 8.0 to 9.8 nM (95–103%) at the serotonin 5-HT2C receptor.[1][2] It showed no agonistic activity at the serotonin 5-HT2B receptor at concentrations of up to 30,000 nM.[1][2] 2-Hydroxy-11-(2-methylallyl)oxynoraporphine was among most potent serotonin 5-HT2A receptor agonists of a large series of assessed noraporphines.[1][2]
The chemical synthesis of 2-hydroxy-11-(2-methylallyl)oxynoraporphine has been described.[1][2] A variety of analogues of the drug with similar activity have also been described.[1][2]
2-Hydroxy-11-(2-methylallyl)oxynoraporphine was first described in the scientific literature by Wangzhi Qin and colleagues in 2025.[1] It had previously been patented in 2022.[2]